Loading clinical trials...
Loading clinical trials...
Study of the efficacy and safety of aliskiren when added to losartan and optimal antihypertensive therapy in patients with hypertension, type 2 diabetes, and kidney disorders to monitor improvement in...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Novartis Pharmaceuticals
NCT06843304 · Diabetic Nephropathy, T2DM
NCT01802034 · Kidney Diseases, Kidney Failure, Chronic, and more
NCT06833541 · Diabetic Nephropathy Type 2, Type 2 Diabetes Mellitus (T2DM), and more
NCT06661174 · Bariatric Surgeries, Diabetic Nephropathy
NCT04931537 · Diabetic Nephropathy Type 2, Biomarker
Novartis Pharmaceuticals
East Hanover, New Jersey
Investigative Site
Québec
Investigative Site
Hillerød
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions